Phase III Trial of Lenvatinib (LEN) vs Sorafenib (SOR) in First-Line Treatment of Patients (PTS) with Unresectable Hepatocellular Carcinoma (uHCC)-MedSci.cn

Phase III Trial of Lenvatinib (LEN) vs Sorafenib (SOR) in First-Line Treatment of Patients (PTS) with Unresectable Hepatocellular Carcinoma (uHCC)

Cheng, AL; Finn, RS; Qin, S; Han, KH; Ikeda, K; Piscaglia, F; Baron, A; Park, JW; Han, G; Jassem, J; Blanc, JF; Vogel, A; Komov, D; Evans, TRJ; Lopez, C; Dutcus, C; MinRen; Kraljevic, S; Tamai, T; Bower, J; Kudo, M

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017; 13 ( ): 116

科室
- - 订阅+
  - 更多科室
工具
服务